Genentech at outperform rating from RBC

RBC Capital Markets analyst Jason Kantor rated Genentech, Inc. at outperform, with average risk. The analyst is not expecting Herceptin sales to suffer from Tykerb data in refractory breast cancer patients. Shares of the South San Francisco, Calif.-based pharmaceutical company were down $2.00, or 2.43%, at $80.29 on volume of 3,004,690 shares versus the three-month running average of 3,537,690 shares. (NYSE: DNA).

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.